Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Testosterone delivery route and growth hormone effects in men with hypogonadism
ACTRN12605000482662Phase 4Recruiting
- Sponsor
- St Vincent's Hospital Sydney
- Start
- Jun 2005
- Modality
- Recombinant Proteins and Enzymes, Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of testosterone and somatropin in Hypoandrogenism (TD), hypopituitarism and growth hormone deficiency (GHD) (2 arms), sponsored by St Vincent's Hospital Sydney. Primary endpoints: Biochemical markers of the growth hormone-insulin-like growth factor axis and bone turnover and Substrate metabolism and protein turnover. Started Jun 2005; status: recruiting.
02
Drugs
testosteronesomatropin
03
Conditions
Hypoandrogenism (TD)hypopituitarismgrowth hormone deficiency (GHD)
Beyond the preview
Go deeper on ACTRN12605000482662.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12605000482662.